ESSEXBIO-TECH：ANNUALREPORT2021.pdf

1、2021 ANNUALREPORT2021 年報年報ANNUAL REPORT 2021PIONEERING GLOBALREGENERATIVESCIENCE&TECHNOLOGY已經 向右移7mmTOMORROWS TODAY2Chairmans Statement10Business Review20Financial Highlights21Financial Review29Profiles of Directors and Senior Management32Report of the Directors53Independent Auditors Report58Consoli

2、dated Statement of Profit or Loss and Other Comprehensive Income59Consolidated Statement of Financial Position60Consolidated Statement of Changes in Equity61Consolidated Statement of Cash Flows63Notes to the Consolidated Financial Statements130Five Year Financial Summary131Corporate Governance Repor

3、t142Corporate InformationCONTENTSCHAIRMANS STATEMENTNgiam Mia Je PatrickChairmanAnnual Report 20213CHAIRMANS STATEMENTOn behalf of the board of directors(the“Board”)of Essex Bio-Technology Limited(the“Company”,together with its subsidiaries,the“Group”),I am pleased to announce that the Group has ach

4、ieved significantly improved financial performances in the financial year ended 31 December 2021.This is a testament that the Groups business is resilient and was able to recover swiftly to the pre-COVID-19 level after the normalcy of the clinical operations of hospitals resumed in the Peoples Repub

5、lic of China(the“PRC”)since September 2020.2021 has been a year full of diverse challenges.Our part of the world has been affected by extended lockdowns and border closures under COVID zero regime,even as other regions begun to reopen.Despite yet another difficult year inflicted by the pandemic of C

6、OVID-19 on us all,the tenacity,drive and leadership in our DNA was able to deliver greater stakeholder value.FINANCIAL PERFORMANCEFor the year ended 31 December 2021,the Group achieved an increase of 67.4%in the consolidated turnover to approximately HK$1,637.7 million as compared to approximately H